Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)
Status:
Completed
Trial end date:
1996-12-01
Target enrollment:
Participant gender:
Summary
To determine if HIV hyperimmune globulin (HIVIG) given to HIV-positive pregnant women during
the second and third trimester of pregnancy reduced the likelihood of maternal-fetal HIV
transmission. Conducted in collaboration with the National Institute of Child Health and
Human Development and the National Institute of Allergy and Infectious Diseases. The trial
was Pediatric ACTG Protocol 185.
Phase:
Phase 3
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institute of Allergy and Infectious Diseases (NIAID)